Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut Pasteur | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary Objectives:
Assess whether CL (caused by Leishmaniasis major) lesions treated with WR279396 improved the cosmetic outcome compared with no treatment (natural healing)
Secondary Objectives
Evaluate the cosmetic outcome of CL lesions treated with "vehicle" compared with no treatment (natural healing)
Evaluate the cosmetic outcome of CL lesions treated with "vehicle" compared with WR279396
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| WR 279,396 | Experimental | CL lesions treated with WR 279396 |
|
| Natural Healing | No Intervention | CL lesions healed naturally | |
| vehicle control | Placebo Comparator | CL lesions were treated with the vehicle alone |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WR 279396 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cosmetic outcome based on modified Vancouver Scar Score (mVSS) | The primary cosmetic outcome measure is the Clinical Scar Rating, based on a modified Vancouver Scar Score (mVSS). The primary efficacy endpoint is the percent of persons judged to have either a "superior (no scar)" or "excellent" rating (see below). | Day 360 or greater |
Not provided
Not provided
Inclusion Criteria:
Included are volunteers who participated in WRAIR 813 (HSRRB Log # 9768.1) and those who participated in another CL study in/around the WRAIR 813 study site who had been assigned to a "no-treatment" (natural healing) arm. All volunteers will have had documented CL in the past that were treated with WR279396, vehicle, or no treatment (natural history), have signed informed consent, and are willing to comply with study assessments; age range: 5 to 75 years old.
For study subjects who were enrolled in WRAIR 813 in 2004 (WR279396 or vehicle treated):
Study subjects from the earlier studies to serve as "no treatment" controls:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| COL Doug Walsh, MD | Walter Reed Army Institute of Research (WRAIR) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute Pasteur de Tunis | Tunis | 1002 | Tunisia |
Not provided
| ID | Term |
|---|---|
| D016773 | Leishmaniasis, Cutaneous |
| D002921 | Cicatrix |
| ID | Term |
|---|---|
| D007896 | Leishmaniasis |
| D056986 | Euglenozoa Infections |
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D007239 |
| Infections |
| D012876 | Skin Diseases, Parasitic |
| D000079426 | Vector Borne Diseases |
| D012874 | Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |